Theriva Biologics Reports Q1 2026 Financial Results with Improved Loss and First Revenue Generation

Theriva Biologics, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $2.0 million, or $0.05 per share, a significant improvement from a net loss of $4.3 million, or $1.55 per share, in the same period last year. The company recognized $300,000 in license revenue, marking its first revenue generation, while total operating costs decreased to $2.4 million from $4.4 million year-over-year, primarily due to reduced research and development expenses. The decrease in operating costs was attributed to the completion of the Phase 2b clinical trial for its lead product candidate, VCN-01, and the recognition of a Spanish research and development rebate.

In terms of financial position, Theriva reported cash and cash equivalents of approximately $14.4 million as of March 31, 2026, an increase from $13.1 million at the end of 2025. The company raised approximately $2.3 million through the sale of 10.2 million shares under its At The Market Issuance Sales Agreement during the quarter. The accumulated deficit stood at $360.8 million, reflecting the ongoing challenges in achieving profitability. The company continues to face uncertainties regarding its ability to secure additional funding, which is critical for its ongoing clinical trials and operational activities.

Strategically, Theriva has made significant moves, including the licensing agreement with Rasayana Therapeutics for its SYN-020 product, which is expected to provide up to $16 million in development milestone payments and $22 million in sales milestone payments, along with tiered royalties on net sales. This agreement allows Theriva to focus its resources on its oncology pipeline, particularly VCN-01, which is currently in clinical trials for pancreatic cancer and retinoblastoma. The company is also planning a Phase 2a study to evaluate more frequent dosing of VCN-01, with the aim of enhancing treatment efficacy.

Operationally, Theriva has streamlined its workforce, reducing its employee count by 32% in September 2025 to focus on business development and clinical trial preparations. The company has administered VCN-01 to 144 patients across various trials, and it is actively pursuing additional clinical studies to further its product development. The company’s strategic focus on oncology, combined with its recent licensing agreement, positions it to potentially enhance its market presence and financial stability.

Looking ahead, Theriva Biologics acknowledges the need for additional capital to fund its clinical trials and operational expenses. The company is exploring various financing options, including equity and debt offerings, and is in discussions with institutional investors. However, there is no assurance that it will secure the necessary funding on favorable terms. The management has expressed that the current cash reserves are expected to sustain operations into the first quarter of 2027, but the company remains cautious about its long-term viability without further capital infusion.